Q1 2026 · 13F-HR
Foresite Capital Management VI LLCholdings as filed
Filed 2026-05-15 · accession 0001104659-26-062467
The Brief · Foresite Capital Management VI LLC · Q1 2026
AI · grounded in 13F
Foresite Capital Management VI LLC closed its position in RAPT Therapeutics, Inc. RAPT, reducing exposure by $52.9M. The fund also exited its holdings in Natera, Inc. NTRA for $15.4M and Atai Beckley N.V. ATAI for $11.2M. Offsetting these sales, the fund established new positions in Minerva Neurosciences, Inc. NERV for $11.9M and Celldex Therapeutics, Inc. CLDX for $10M. Additionally, the fund increased its share count in Corvus Pharmaceuticals, Inc. CRVS by 32.6%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG Oncology, Inc. | $150.3M | 32.7% | 2,221,474 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC. | $93.6M | 20.3% | 4,247,670 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals plc | $54.2M | 11.8% | 1,364,019 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals, Inc. | $26.8M | 5.82% | 1,831,233 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $23.2M | 5.05% | 1,209,971 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS, INC. | $17.8M | 3.86% | 525,000 | Common | SOLE |
| 92337C203 | VSTM | Verastem, Inc. | $16.7M | 3.62% | 3,146,631 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $12.2M | 2.65% | 146,332 | Common | SOLE |
| 603380205 | NERV | Minerva Neurosciences, Inc. | $12.0M | 2.60% | 1,986,600 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics, Inc. | $10.0M | 2.18% | 315,913 | Common | SOLE |
| 04650F101 | ATAI | AtaiBeckley Inc. | $9.7M | 2.12% | 2,750,000 | Common | SOLE |
| 433313103 | HNGE | Hinge Health, Inc. | $8.5M | 1.85% | 220,400 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals, Inc. | $7.7M | 1.67% | 212,010 | Common | SOLE |
| 68277Q105 | OKUR | OnKure Therapeutics, Inc. | $6.0M | 1.30% | 1,445,783 | Common | SOLE |
| 008064206 | JBIO | Jade Biosciences, Inc. | $4.5M | 0.98% | 320,000 | Common | SOLE |
| G3855L106 | GHRS | GH Research PLC | $4.4M | 0.96% | 315,492 | Common | SOLE |
| G9TY5A101 | ZURA | Zura Bio Ltd | $2.7M | 0.58% | 450,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.